431 related articles for article (PubMed ID: 18376797)
41. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections.
Balaton AJ; Nehama-Sibony M; Gotheil C; Callard P; Baviera EE
J Pathol; 1988 Dec; 156(4):305-10. PubMed ID: 2465399
[TBL] [Abstract][Full Text] [Related]
42. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
[TBL] [Abstract][Full Text] [Related]
43. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
Lamps LW; Folpe AL
Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
[TBL] [Abstract][Full Text] [Related]
44. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
[TBL] [Abstract][Full Text] [Related]
45. Nucleolar organizer regions in cirrhosis and hepatocellular carcinoma.
Jain R; Malhotra V; Kumar N; Sarin SK
Trop Gastroenterol; 1998; 19(3):100-1. PubMed ID: 9828706
[TBL] [Abstract][Full Text] [Related]
46. Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma.
Yamamoto M; Ariizumi S; Otsubo T; Katsuragawa H; Katagiri S; Nakano M; Takasaki K
J Surg Oncol; 2004 Aug; 87(2):80-3; discussion 83-4. PubMed ID: 15282700
[TBL] [Abstract][Full Text] [Related]
47. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas.
Stroescu C; Herlea V; Dragnea A; Popescu I
J Gastrointestin Liver Dis; 2006 Mar; 15(1):9-14. PubMed ID: 16680226
[TBL] [Abstract][Full Text] [Related]
48. [Anatomo-pathologic diagnostic interpretation of nodular hepatic lesions].
Chiaramondia M; Ceppa P; Baccini P; Badini A; Castellaneta A
Pathologica; 1993; 85(1100):687-99. PubMed ID: 8170717
[TBL] [Abstract][Full Text] [Related]
49. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.
Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ
Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337
[TBL] [Abstract][Full Text] [Related]
50. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
51. A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'.
Kozaka K; Sasaki M; Fujii T; Harada K; Zen Y; Sato Y; Sawada S; Minato H; Matsui O; Nakanuma Y
Histopathology; 2007 Sep; 51(3):390-400. PubMed ID: 17553067
[TBL] [Abstract][Full Text] [Related]
52. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
53. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
54. Primary liver carcinoma arising in people younger than 30 years.
Klein WM; Molmenti EP; Colombani PM; Grover DS; Schwarz KB; Boitnott J; Torbenson MS
Am J Clin Pathol; 2005 Oct; 124(4):512-8. PubMed ID: 16146811
[TBL] [Abstract][Full Text] [Related]
55. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
56. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
Zimmerman RL; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
[TBL] [Abstract][Full Text] [Related]
57. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?
de Boer WB; Segal A; Frost FA; Sterrett GF
Cancer; 2000 Oct; 90(5):273-8. PubMed ID: 11038423
[TBL] [Abstract][Full Text] [Related]
58. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma.
Murakata LA; Ishak KG; Nzeako UC
Mod Pathol; 2000 Aug; 13(8):874-81. PubMed ID: 10955454
[TBL] [Abstract][Full Text] [Related]
59. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract][Full Text] [Related]
60. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]